N-PORT filing recap · October 2021

What did ARK Genomic Revolution ETF buy in October 2021?

Reported stock-position changes between this filing and the previous one. These are ARK Genomic Revolution ETF's own holdings, not the firm's.

Stock value

$7.21B

Positions

Estimated turnover

31.4%

Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.

New positions

DNAGinkgo Bioworks Holdings, Inc.$218.41Mreported value+15.80M shares PFEPfizer Inc.$97.10Mreported value+2.22M shares SLGCUSDSomalogic Inc$95.46Mreported value+7.50M shares PLTRPalantir Technologies Inc.$42.22Mreported value+1.63M shares

Increased positions

TDOCTeladoc Health, Inc.$645.49Mreported value+315.3K shares+7.9%EXASExact Sciences Corporation$392.44Mreported value+78.3K shares+1.9%PACBPacific Biosciences of California, Inc.$383.41Mreported value+156.4K shares+1.1%FATEFate Therapeutics, Inc.$258.13Mreported value+481.7K shares

Reduced positions

IONSIonis Pharmaceuticals, Inc.$271.67Mreported value-501.2K shares-5.6%VRTXVertex Pharmaceuticals Inc / Ma$270.50Mreported value-350.4K shares-19.3%TWSTTwist Bioscience Corporation$262.34Mreported value-260.6K shares-10.6%INCYIncyte Corporation$192.70Mreported value-169.2K shares

Exited positions

NVSNovartis AG$233.56Mprior reported value-2.53M shares-100.0%RHHBYRoche Holding AG$212.70Mprior reported value-4.41M shares-100.0%BMYBristol-Myers Squibb Company$88.23Mprior reported value-1.30M shares-100.0%SMFRGenedx Holdings Corp$51.11Mprior reported value-4.53M shares